ClinicalTrials.gg
Drug

Darolutamide clinical trials

Also written Nubeqa, ODM-201 and BAY 1841788.

studies test it
77
open now
33
in phase 3
16
first study started
2011

How each study uses darolutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the darolutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Jul 2019 · NUBEQA · NDA 212099 (FDA, Drugs@FDA)
European Union
27 Mar 2020 · Nubeqa · EMEA/H/C/004790 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Darolutamide
41
Antiandrogen ODM-201
7
Darolutamide (Nubeqa, BAY1841788)
5
Darolutamide 300 mg
3
Darolutamide (BAY1841788, Nubeqa)
2

Brand

Nubeqa
20

Development codes

ODM-201
18
BAY 1841788
13

Studies by the year they started

76 studies that test it; most in 2026 (11); 1 more planned to start later

Studies that test darolutamide, by start year
YearStudies
20112
20131
20141
20152
20163
20176
20183
20192
20206
202110
20225
202310
20249
20255
202611

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
18
Phase 2
43
Phase 3
16
Phase 4
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 51

Bayer (16) · Orion Corporation, Orion Pharma (4) · UNICANCER (3) · National Cancer Institute (NCI) (2) · ECOG-ACRIN Cancer Research Group (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Peking University First Hospital (2) · AdventHealth (1)

Often tested with

Tested in the same studies.

Leuprolide (5) · Enzalutamide (5) · Docetaxel (4) · Antiandrogens (4) · Abiraterone (4) · Relugolix (3) · Degarelix (3) · Bicalutamide (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 11, 3 in phase 3

Studies that test darolutamide, phase 3 first.

Studies

Open first, then newest update. How each study uses darolutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 77

See all 77 studies that test darolutamide →

Given beside what is tested · 22 — darolutamide is usual care or a partner of the new treatment

Showing 20 of 22.

As the comparator · 2 — what is tested is compared with darolutamide

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call darolutamide · ClinicalTrials.gg INT000459

  • MeSH (NLM) C000607739darolutamideOne source ClinicalTrials.gov
  • UNII (FDA) X05U0N2RCODAROLUTAMIDEConfirmed FDA, Wikidata
  • RxNorm 2180325Confirmed FDA, Wikidata
  • Wikidata Q25091391darolutamideConfirmed FDA, Wikidata
  • NCI Thesaurus C104748DarolutamideOne source FDA
  • DrugBank DB12941One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.